In vivo bioluminescence tumor imaging of RGD peptide-modified adenoviral vector encoding firefly luciferase reporter gene

Molecular Imaging and Biology

Volumn 9, Issue 3, 2007, Pages 126-134

  Niu, Gang ^a,b   Xiong, Zhengming ^b   Cheng, Zhen ^b   Cai, Weibo ^b   Gambhir, Sanjiv S ^b   Xing, Lei ^a   Chen, Xiaoyuan ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Adenovirus; Bioluminescence imaging; Firefly luciferase; Integrin v 3; Reporter gene; RGD

Indexed keywords

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; FIREFLY LUCIFERASE; MACROGOL; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG TARGETING; FEASIBILITY STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSDUCTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTIVITY;

ADENOVIRUSES, HUMAN; ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; FEMALE; GENE EXPRESSION; GENES, REPORTER; GENETIC VECTORS; HUMANS; INTEGRIN ALPHAVBETA3; LUCIFERASES, FIREFLY; LUMINESCENT MEASUREMENTS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECEPTORS, VIRUS; RECOMBINANT PROTEINS; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; CYTOMEGALOVIRUS; HUMAN ADENOVIRUS;

EID: 34248201700     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-007-0079-2     Document Type: Article

References (53)

1. McConnell MJ, Imperiale MJ (2004) Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 15:1022-1033
2. Bergelson JM, Cunningham JA, Droguett G, et al. (1997) Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320-1323
3. Hemminki A, Kanerva A, Liu B, et al. (2003) Modulation of Coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res 63:847-853
4. Huard J, Lochmuller H, Acsadi G, et al. (1995) The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther 2:107-115
5. Sullivan DE, Dash S, Du H, et al. (1997) Liver-directed gene transfer in non-human primates. Hum Gene Ther 8:1195-1206
6. Tomanin R, Scarpa M (2004) Why do we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction. Curr Gene Ther 4:357-372
7. Akporiaye ET, Hersh E (1999) Clinical aspects of intratumoral gene therapy. Curr Opin Mol Ther 1:443-453
8. Mizuguchi H, Koizumi N, Hosono T, et al. (2001) A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther 8:730-735
9. Mizuguchi H, Hayakawa T (2002) Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes. Gene 285:69-77
10. Mizuguchi H, Hayakawa T (2004) Targeted adenovirus vectors. Hum Gene Ther 15:1034-1044
11. Stevenson SC, Rollence M, Marshall-Neff J, McClelland A (1997) Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J Virol 71:4782-4790
12. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A (2000) Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol 74:2567-2583
13. Koizumi N, Mizuguchi H, Utoguchi N, Watanabe Y, Hayakawa T (2003) Generation of fiber-modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob. J Gene Med 5:267-276
14. Watkins SJ, Mesyanzhinov VV, Kurochkina LP, Hawkins RE (1997) The 'adenobody' approach to viral targeting: Specific and enhanced adenoviral gene delivery. Gene Ther 4:1004-1012
15. Goldman CK, Rogers BE, Douglas JT, et al. (1997) Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res 57:1447-1451
16. Sosnowski BA, Gu DL, D'Andrea M, Doukas J, Pierce GF (1999) FGF2-targeted adenoviral vectors for systemic and local disease. Curr Opin Mol Ther 1:573-579
17. Douglas JT, Miller CR, Kim M, et al. (1999) A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat Biotechnol 17:470-475
18. Fisher KD, Stallwood Y, Green NK, et al. (2001) Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther 8:341-348
19. O'Riordan CR, Lachapelle A, Delgado C, et al. (1999) PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 10:1349-1358
20. Croyle MA, Yu QC, Wilson JM (2000) Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Hum Gene Ther 11:1713-1722
21. Croyle MA, Chirmule N, Zhang Y, Wilson JM (2001) "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol 75:4792-4801
22. Croyle MA, Chirmule N, Zhang Y, Wilson JM (2002) PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther 13:1887-1900
23. Eto Y, Gao JQ, Sekiguchi F, et al. (2005) PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J Gene Med 7:604-612
24. Green NK, Herbert CW, Hale SJ, et al. (2004) Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther 11:1256-1263
25. Lanciotti J, Song A, Doukas J, et al. (2003) Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. Mol Ther 8:99-107
26. Ogawara K, Rots MG, Kok RJ, et al. (2004) A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum Gene Ther 15:433-443
27. Hynes RO (2002) Integrins: Bidirectional, allosteric signaling machines. Cell 110:673-687
28. Guo W, Giancotti FG (2004) Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5:816-826
29. Jin H, Varner J (2004) Integrins: Roles in cancer development and as treatment targets. Br J Cancer 90:561-565
30. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164
31. Kerr JS, Slee AM, Mousa SA (2002) The alpha v integrin antagonists as novel anticancer agents: An update. Expert Opin Investig Drugs 11:1765-1774
32. Shannon KE, Keene JL, Settle SL, et al. (2004) Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247. Clin Exp Metastasis 21:129-138
33. 3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 62:4263-4272
34. 3. Clin Cancer Res 6:3056-3061
35. 3 integrin expression using 18 F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61:1781-1785
36. 3-integrin expression. J Nucl Med 45:1776-1783
37. 3 integrin binding peptides in a nude mouse model. Cancer Res 62:6146-6151
38. 3 in brain tumor xenografts. Cancer Res 64:8009-8014
39. Liang Q, Nguyen K, Satyamurthy N, et al. (2002) Monitoring adenoviral DNA delivery, using a mutant herpes simplex virus type 1 thymidine kinase gene as a PET reporter gene. Gene Ther 9:1659-1666
40. 3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene. J Nucl Med 47:130-139
41. Read ML, Etrych T, Ulbrich K, Seymour LW (1999) Characterisation of the binding interaction between poly(L-lysine) and DNA using the fluorescamine assay in the preparation of non-viral gene delivery vectors. FEBS Lett 461:96-100
42. Smith AE (1995) Viral vectors in gene therapy. Annu Rev Microbiol 49:807-838
43. Thomas CE, Ehrhardt A, Kay MA (2003) Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4:346-358
44. Wu JC, Sundaresan G, Iyer M, Gambhir SS (2001) Noninvasive optical imaging of firefly luciferase reporter gene expression in skeletal muscles of living mice. Mol Ther 4:297-306
45. Zhang X, Xiong Z, Wu X, et al. (2005) Quantitative PET imaging of tumor integrin avb3 expression with [18 F]FRGD2. J Nucl Med 47:492-501
46. Alemany R, Suzuki K, Curiel DT (2000) Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 81:2605-2609
47. Mok H, Palmer DJ, Ng P, Barry MA (2005) Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 11:66-79
48. Rolland A, Collet B, Le Verge R, Toujas L (1989) Blood clearance and organ distribution of intravenously administered polymethacrylic nanoparticles in mice. J Pharm Sci 78:481-484
49. Doran JE, Lundsgaard-Hansen P (1988) Role of the reticuloendothelial system in the pathogenesis of organ damage. Br J Hosp Med 39:221-225
50. Contag CH, Bachmann MH (2002) Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng 4:235-260
51. Gross S, Piwnica-Worms D (2005) Spying on cancer: Molecular imaging in vivo with genetically encoded reporters. Cancer Cell 7:5-15
52. Gambhir SS, Barrio JR, Phelps ME, et al. (1999) Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. Proc Natl Acad Sci USA 96:2333-2338
53. Gambhir SS, Bauer E, Black ME, et al. (2000) A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci USA 97:2785-2790